LXRX (STOCKS)
Lexicon Pharmaceuticals, Inc.
$1.930000
+0.010000 (+0.52%)
Prev close: $1.920000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Exton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $870.62M
- Employees
- 103
- P/E (TTM)
- -27.41
- P/B (TTM)
- 4.01
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.00 | $-0.04 | +0.0351 | +100.00% |
|
Dec 2025 (Q4)
|
$-0.04 | $-0.07 | +0.0304 | +43.18% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.07 | +0.0273 | +40.56% |
|
Jun 2025 (Q2)
|
$0.01 | $-0.08 | +0.0891 | +112.64% |
Financial Statements
| Revenues | $69.64M |
| Benefits Costs and Expenses | $93.87M |
| Cost Of Revenue | $352.00K |
| Costs And Expenses | $93.87M |
| Gross Profit | $69.29M |
| Operating Expenses | $93.52M |
| Selling, General, and Administrative Expenses | $34.94M |
| Research and Development | $58.58M |
| Operating Income/Loss | -$24.23M |
| Income/Loss From Continuing Operations After Tax | -$26.09M |
| Income/Loss From Continuing Operations Before Tax | -$24.71M |
| Net Income/Loss | -$26.09M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$26.09M |
| Net Income/Loss Available To Common Stockholders, Basic | -$26.09M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.07 |
| Diluted Earnings Per Share | -$0.07 |
| Basic Average Shares | 1,127,059,000 |
| Diluted Average Shares | 1,127,335,000 |
| Assets | $268.82M |
| Current Assets | $186.03M |
| Inventory | $276.00K |
| Other Current Assets | $185.76M |
| Noncurrent Assets | $82.79M |
| Fixed Assets | $1.75M |
| Other Non-current Assets | $81.03M |
| Liabilities | $65.96M |
| Current Liabilities | $9.90M |
| Accounts Payable | $3.00M |
| Wages | $2.75M |
| Other Current Liabilities | $4.16M |
| Noncurrent Liabilities | $56.07M |
| Equity | $202.86M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $202.86M |
| Liabilities And Equity | $268.82M |
| Net Cash Flow From Operating Activities | -$38.80M |
| Net Cash Flow From Operating Activities, Continuing | -$38.80M |
| Net Cash Flow From Investing Activities | $2.18M |
| Net Cash Flow From Investing Activities, Continuing | $2.18M |
| Net Cash Flow From Financing Activities | $40.83M |
| Net Cash Flow From Financing Activities, Continuing | $40.83M |
| Net Cash Flow | $4.20M |
| Net Cash Flow, Continuing | $4.20M |
| Comprehensive Income/Loss | -$26.21M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$26.25M |
| Other Comprehensive Income/Loss | -$29.46M |